Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 73.31M P/E - EPS this Y 68.20% Ern Qtrly Grth -
Income -22.37M Forward P/E -0.16 EPS next Y -26.20% 50D Avg Chg -32.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.92 EPS next 5Y - 52W High Chg -85.00%
Recommedations 1.50 Quick Ratio 10.38 Shares Outstanding 10.56M 52W Low Chg 18.00%
Insider Own 8.24% ROA -49.60% Shares Float 5.49M Beta 0.90
Inst Own 69.07% ROE -91.68% Shares Shorted/Prior 59.08K/66.45K Price 2.62
Gross Margin - Profit Margin - Avg. Volume 313,865 Target Price 19.00
Oper. Margin - Earnings Date Nov 11 Volume 65,333 Change -9.97%
About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc. News
11/14/24 Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
11/04/24 Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
10/14/24 Benitec Biopharma Announces Updated Investor Webcast Information
10/12/24 Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
09/30/24 Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc
09/28/24 Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
09/26/24 Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
09/18/24 Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
09/17/24 Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
07/15/24 Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
07/01/24 Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
05/13/24 Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
05/01/24 Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
04/18/24 Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
04/18/24 Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
04/09/24 Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
03/24/24 11 Best ASX Stocks To Buy Now
02/13/24 Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
11/30/23 Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
11/30/23 Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns
BNTC Chatroom

User Image gabyrig Posted - 5 days ago

@KingOfTheSwingers But... What I'm looking at on the $ITRM is for sign of big time flippers getting in either for buyout or long hold. Not you and me buying 10K shares but real dollars from institutions, hedge funds, retirement funds, LLCs etc. They're all in cahoots with the analysts and that's for they decide to buy. So that's why I'm also looking at who is covering the ticker and what price they're setting. Just like BNTC, I expect those targets to be raised (it can take months) and I expect the price to go up. With the analysts and tutes, you'll notice the volume is crap but price keeps going up. The one issue here though is these people will need money to keep their pockets happy and it will come in the form of dilution into the SP. The decision becomes, with my shares, do I add more and get out when it ticks up again or do I wait for news that can take 3-6-12 months. In the case of $BNTC, I took my profit and did well. PT on that is as much as 32 bucks I think but I'm good.

User Image gabyrig Posted - 5 days ago

$BNTC Mad quiet here. What's the craic?

User Image Jinimation Posted - 1 week ago

$BNTC what is going on?

User Image tedtalks24 Posted - 2 weeks ago

$BNTC what does this mean

User Image DonCorleone77 Posted - 2 weeks ago

$BNTC Benitec Biopharma files $125M mixed securities shelf

User Image gabyrig Posted - 10/28/24

$ITRM This reminds me of $BNTC. Still no announcement of buyout that I know of but it moved like one. Set my own PT then was out with my bag. It's still climbing but that's none of my business. I expect something similar here so it's worth a ride for analysts to start putting out PTs, PR from company, etc. If BO news come out, great. If not, just exit on my own PT. No need to linger anymore. Manage your trade, flip or investment. All that matters is we make money. Good luck all!

User Image Doozio Posted - 10/26/24

$BNTC it’s da FUTUre of 🧠⏰ n da pump ain’t even begun BAHt NOW wUtch them 🐑🩳s enter da FTEL pos during 🧠⏰♾️

User Image justiceforb_85 Posted - 10/25/24

$BNTC steadily been increasing. Will have a MOAT with Oculopharyngeal Muscular Dystrophy (OPMD) treatment.

User Image Americanbulls Posted - 1 month ago

$BNTC the bull pattern is confirmed & a BUY signal is issued @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=BNTC. Buy Level: 10.43 Target: 26.28

User Image TB_Goat Posted - 1 month ago

$BNTC nice ascending wedge on the daily chart

User Image justiceforb_85 Posted - 1 month ago

$BNTC $XBI great news on treatment for oculopharyngeal muscular dystrophy. https://www.benitec.com/for-investors/news-events/press-releases/detail/121/benitec-biopharma-reports-positive-data-from-two-subjects-treated-with-low-dose-bb-301-in-phase-1b2a-study-presented-at-29th-annual-congress-of-the-world-muscle-society

User Image Doozio Posted - 1 month ago

$BNTC da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️

User Image tedtalks24 Posted - 1 month ago

$BNTC they just dumped more shares Gona crash so hard

User Image tedtalks24 Posted - 1 month ago

$BNTC dumping on you again

User Image tedtalks24 Posted - 1 month ago

$BNTC trash scam

User Image tedtalks24 Posted - 1 month ago

$BNTC I won’t stop warning you all. I’ve filed a complaint with the sec

User Image tedtalks24 Posted - 1 month ago

$BNTC scam scam

User Image tedtalks24 Posted - 1 month ago

$BNTC what a rug pulling Joke of a scam this is

User Image tedtalks24 Posted - 1 month ago

$BNTC scam scam rug pull

User Image tedtalks24 Posted - 1 month ago

$BNTC dog shit scam

User Image tedtalks24 Posted - 1 month ago

$BNTC forget my last comment it’s dumped right back down

User Image tedtalks24 Posted - 1 month ago

$BNTC anyone know why this is pumping?

User Image MBFG09 Posted - 1 month ago

$BNTC $IMMP benitec is performing better than Immutep I’m very happy for Australian brothers

User Image Northeast14 Posted - 1 month ago

$BNTC worth taking a look at $GENFF away to start human and dog trials on longevity

User Image DipBuyInvester Posted - 09/30/24

$BNTC Dast money TANH!! Mark it!!

User Image DonCorleone77 Posted - 09/26/24

$BNTC Benitec Biopharma reports FY24 EPS ( $5.51) vs ($14.12) in FY23 Total Revenues for the year ended June 30, 2024, were $0 million compared to $75K in licensing revenues collected for the year ended June 30."The 90-day and 180-day interim clinical study results for the first subject enrolled into the low-dose cohort of the BB-301 Phase 1b/2a Clinical Treatment Study demonstrated clinically meaningful improvements in the central study endpoints, with significant improvements noted across the radiographic assessments of swallowing efficiency and corresponding improvements observed for the key dysphagia-focused subject-reported outcome measure," said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. "Additional clinical data for the BB-301 Phase 1b/2a Clinical Treatment Study were accepted for oral presentation during the Late Breaking session of the 29th Annual Congress of the World Muscle Society on October 12, 2024. The recent financing comfortably positions Benitec to advance the BB-301 clinical development program through the end of 2025.". As of June 30, , the Company had $50.9M in cash.

User Image Stock_Titan Posted - 09/26/24

$BNTC Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update https://www.stocktitan.net/news/BNTC/benitec-biopharma-releases-full-year-2024-financial-results-and-a76b6uz0d7tz.html

User Image Stock_Titan Posted - 2 months ago

$BNTC Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society https://www.stocktitan.net/news/BNTC/benitec-biopharma-announces-late-breaking-oral-abstract-presentation-4sk6tpxkd4ln.html

User Image justiceforb_85 Posted - 2 months ago

$BNTC $XBI promising data and most advanced product for treatment of oculopharyngeal muscular dystrophy.

User Image ChiefInspector1 Posted - 2 months ago

$TNXP 🚀🚀🚀 $PFE $BNTC https://www.marketscreener.com/quote/stock/TONIX-PHARMACEUTICALS-HOL-154457268/news/Tonix-Pharmaceuticals-Holding-Corp-announces-an-Equity-Buyback-for-10-million-worth-of-its-shares-47826568/

Analyst Ratings
Leerink Partners Outperform Jul 22, 24
Piper Sandler Overweight Jun 13, 24
JMP Securities Market Outperform Apr 22, 24
JMP Securities Market Outperform Feb 15, 24
JMP Securities Market Outperform Jan 24, 24
JMP Securities Market Outperform Sep 26, 23